SAN FRANCISCO , Nov. 13, 2019 /PRNewswire/ -- Akero Therapeutics, Inc.  (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that members of the

SAN FRANCISCO , Nov. 12, 2019 /PRNewswire/ -- Akero Therapeutics, Inc.  (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today reported third quarter 2019

Akero Therapeutics is thrilled to announce that its chief development officer Kitty Yale has been recognized by FiercePharma as one of 2019's “Fiercest Women in Life Sciences.” Kitty joined Akero from Gilead Sciences, Inc. where she led global clinical operations and management of the company’s

3D InSight™ Human Liver Disease Platform will be used to screen effects of Akero lead program AKR-001 on underlying metabolic and fibrotic drivers of NAFLD and NASH. SCHLIEREN, Switzerland and SAN FRANCISCO, Oct. 3, 2019 /PRNewswire/ -- Akero Therapeutics and InSphero AG today announced that Akero

SAN FRANCISCO , Sept. 4, 2019 /PRNewswire/ --  Akero Therapeutics, Inc.  (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that members of the

-- Advanced AKR-001 into Phase 2a BALANCED clinical study in NASH -- -- Raised $98.4 million in aggregate net proceeds from Initial Public Offering -- SAN FRANCISCO , Aug. 12, 2019 /PRNewswire/ -- Akero Therapeutics, Inc.  (Nasdaq: AKRO), a clinical-stage biotechnology company developing

SAN FRANCISCO , July 2, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced the dosing of the first

SAN FRANCISCO , June 24, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for people with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced the closing of its initial

SAN FRANCISCO , June 19, 2019 /PRNewswire/ --  Akero Therapeutics, Inc. (NASDAQ: AKRO), a clinical-stage biotechnology company developing transformational treatments for people with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced the pricing of its

SAN FRANCISCO, May 29, 2019 /PRNewswire/ -- Akero Therapeutics, Inc., a biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases, today announced that it has screened the first patient for its Phase 2a clinical trial